All In Biotech

Drug Trial Radar · NCT06952660

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

A PROSPECTIVE LOW-INTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK® IN RECURRENT OR METASTATIC CERVICAL CANCER

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

May 7, 2025

Primary completion

Dec 13, 2028

Study completion Dec 13, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Genmab
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease. * This study is seeking for participants who: Are willing to take all the required eye tests * Have not received TIVDAK before * Do not have any active eye issues. Participants will receive TIVDAK once every 3 weeks as an infusion that will be injected into the vein. Participants will visit an eye care provider at 3 stages: * before starting the treatment, * before each of the first 9 infusions * then monthly for 3 months after they stop taking TIVDAK. Treatment with TIVDAK will continue until it is not working anymore against the participant's cancer.

Conditions

  • Cervical Cancer

Interventions

  • TIVDAKDrug

    2 mg/kg once every 3 weeks (Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Type, incidence and severity of ocular adverse events (AEs)Time frame: 90 days after the last dose of tisotumab vedotin

Locations

135 sites in 2 countries. Site status is shown where the registry gives one.

  • HonorHealth Cancer Care - Biltmore - AZCCC Imaging

    Phoenix, Arizona · Recruiting

  • HonorHealth Cancer Care - Biltmore - HonorHealth Research Pharmacy

    Phoenix, Arizona · Recruiting

  • HonorHealth Research Institute (Arizona Center for Cancer Care) - HonorHealth Cancer Care -Biltmore

    Phoenix, Arizona · Recruiting

  • Sonora Quest Laboratories, LLC

    Phoenix, Arizona · Recruiting

  • South West Medical Imaging (SMIL)

    Phoenix, Arizona · Recruiting

  • Schwartz Laser Eye Center

    Scottsdale, Arizona · Recruiting

  • Virginia G. Piper Cancer Pharmacy - HonorHealth Research Pharmacy

    Scottsdale, Arizona · Recruiting

  • HonorHealth Cancer Care - Tempe - AZCCC Imaging

    Tempe, Arizona · Recruiting

  • HonorHealth Research Institute (Arizona Center for Cancer Care) - HonorHealth Cancer Care - Tempe

    Tempe, Arizona · Recruiting

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California · Recruiting

  • AdventHealth Hematology and Oncology Denver

    Denver, Colorado · Recruiting

  • AdventHealth Medical Group Gynecologic Oncology at Porter

    Denver, Colorado · Recruiting

  • Mount Sinai Comprehensive Cancer Center - Aventura

    Aventura, Florida · Recruiting

  • Florida Cancer Specialists

    Bonita Springs, Florida · Recruiting

  • Florida Cancer Specialists

    Bradenton, Florida · Recruiting

  • Florida Cancer Specialists

    Cape Coral, Florida · Recruiting

  • Broward Health Coral Springs

    Coral Springs, Florida · Recruiting

  • Florida Cancer Specialists

    Daytona Beach, Florida · Recruiting

  • Broward Health North

    Deerfield Beach, Florida · Recruiting

  • Florida Cancer Specialists

    Fleming Island, Florida · Recruiting

  • Broward Health Imperial Point

    Fort Lauderdale, Florida · Recruiting

  • Broward Health Medical Center

    Fort Lauderdale, Florida · Recruiting

  • Florida Cancer Specialists

    Fort Myers, Florida · Recruiting

  • Florida Cancer Specialists

    Fort Myers, Florida · Recruiting

  • HCA Mercy Hospital

    Miami, Florida · Recruiting

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida · Recruiting

  • Mount Sinai Medical Center of Florida, Inc

    Miami Beach, Florida · Recruiting

  • Florida Cancer Specialists

    N. Venice, Florida · Recruiting

  • Florida Cancer Specialists

    Naples, Florida · Recruiting

  • AdventHealth

    Orlando, Florida · Recruiting

  • AdventHealth Gynecologic Oncology

    Orlando, Florida · Recruiting

  • AdventHealth Orlando Infusion Center

    Orlando, Florida · Recruiting

  • AdventHealth

    Orlando, Florida · Recruiting

  • Orlando Health Ambulatory Care Center

    Orlando, Florida · Recruiting

  • Orlando Health Cancer Institute

    Orlando, Florida · Recruiting

  • Orlando Health Orlando Regional Medical Center

    Orlando, Florida · Recruiting

  • Orlando Health Winnie Palmer Hospital for Women & Babies

    Orlando, Florida · Recruiting

  • Florida Cancer Specialists

    Palm Beach Gardens, Florida · Recruiting

  • Florida Cancer Specialists

    Port Charlotte, Florida · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

Showing 40 of 135 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.